Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels

Autores
Elgart, Jorge Federico; Silvestrini Viola, Constanza; Prestes, Mariana; González, Lorena; Rucci, Enzo; Gagliardino, Juan José
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Aims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: On Target (OT; HbA1c≤7%), and Not on Target (NOT; HbA1c>7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycemia treatment and HbA1c values. Results: 48.9% of the participants have HbA1c on target values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycemia drugs treatment was significant associated with glycemic control (OR:0.705), diabetes duration (OR:1.017), systolic blood pressure (OR:1.006), and treatment of T2D (OR:2.622). Conclusions: HbA1c not on target significantly increases drugs monthly cost of hyperglycemia treatment in people with T2D in a country with an emerging market economy. This article is protected by copyright. All rights reserved.
Centro de Endocrinología Experimental y Aplicada
Facultad de Ciencias Económicas
Instituto de Investigación en Informática
Materia
Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-nd/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/142726
Acceder
id SEDICI_ff57cb375ecd2c8deaeec842ddd6d6c8
oai_identifier_str oai:sedici.unlp.edu.ar:10915/142726
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levelsElgart, Jorge FedericoSilvestrini Viola, ConstanzaPrestes, MarianaGonzález, LorenaRucci, EnzoGagliardino, Juan JoséCiencias MédicasCiencias Económicastratamiento de drogascontrol de glucemiadiabetes mellitusPaís en desarrolloAims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: On Target (OT; HbA1c≤7%), and Not on Target (NOT; HbA1c>7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycemia treatment and HbA1c values. Results: 48.9% of the participants have HbA1c on target values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycemia drugs treatment was significant associated with glycemic control (OR:0.705), diabetes duration (OR:1.017), systolic blood pressure (OR:1.006), and treatment of T2D (OR:2.622). Conclusions: HbA1c not on target significantly increases drugs monthly cost of hyperglycemia treatment in people with T2D in a country with an emerging market economy. This article is protected by copyright. All rights reserved.Centro de Endocrinología Experimental y AplicadaFacultad de Ciencias EconómicasInstituto de Investigación en Informática2019-02-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/142726enginfo:eu-repo/semantics/altIdentifier/issn/1742-1241info:eu-repo/semantics/altIdentifier/doi/10.1111/ijcp.13336info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-10T12:39:06Zoai:sedici.unlp.edu.ar:10915/142726Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-10 12:39:06.837SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
spellingShingle Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
Elgart, Jorge Federico
Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
title_short Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_full Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_fullStr Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_full_unstemmed Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_sort Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
dc.creator.none.fl_str_mv Elgart, Jorge Federico
Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
author Elgart, Jorge Federico
author_facet Elgart, Jorge Federico
Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
author_role author
author2 Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
topic Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
dc.description.none.fl_txt_mv Aims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: On Target (OT; HbA1c≤7%), and Not on Target (NOT; HbA1c>7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycemia treatment and HbA1c values. Results: 48.9% of the participants have HbA1c on target values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycemia drugs treatment was significant associated with glycemic control (OR:0.705), diabetes duration (OR:1.017), systolic blood pressure (OR:1.006), and treatment of T2D (OR:2.622). Conclusions: HbA1c not on target significantly increases drugs monthly cost of hyperglycemia treatment in people with T2D in a country with an emerging market economy. This article is protected by copyright. All rights reserved.
Centro de Endocrinología Experimental y Aplicada
Facultad de Ciencias Económicas
Instituto de Investigación en Informática
description Aims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: On Target (OT; HbA1c≤7%), and Not on Target (NOT; HbA1c>7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycemia treatment and HbA1c values. Results: 48.9% of the participants have HbA1c on target values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycemia drugs treatment was significant associated with glycemic control (OR:0.705), diabetes duration (OR:1.017), systolic blood pressure (OR:1.006), and treatment of T2D (OR:2.622). Conclusions: HbA1c not on target significantly increases drugs monthly cost of hyperglycemia treatment in people with T2D in a country with an emerging market economy. This article is protected by copyright. All rights reserved.
publishDate 2019
dc.date.none.fl_str_mv 2019-02-15
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/142726
url http://sedici.unlp.edu.ar/handle/10915/142726
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1742-1241
info:eu-repo/semantics/altIdentifier/doi/10.1111/ijcp.13336
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1842904564292911104
score 12.993085

Publicaciones similares